Nanako Jonai

No ORCID on file · 1 paper in corpus

2026

Clinical Impact of Olaparib Dose Reduction Compared with Bevacizumab and Standard-Dose Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer

·doi:10.20944/preprints202603.0787.v1

Objective: Bevacizumab (BEV) and Olaparib (OLA) have demonstrated clinical efficacy as maintenance therapies for first platinum-sensitive recurrent ovarian cancer. However, direct comparisons between these agents independent of homologous …